Analyzing ENDRA Life Sciences and Waters Corporations

Comparing the medical companies on key metrics like profitability, valuation, and institutional ownership

Jan. 29, 2026 at 5:15am

Got story updates? Submit your updates here. ›

This article compares the business performance and outlook of two medical companies, ENDRA Life Sciences (NASDAQ:NDRA) and Waters Corporation (NYSE:WAT). It analyzes factors like profitability, valuation, risk, institutional ownership, and analyst recommendations to determine which company is the better investment.

Why it matters

Understanding the relative strengths and weaknesses of ENDRA Life Sciences and Waters can help investors make more informed decisions about which medical stock to potentially add to their portfolio. The analysis provides insights into the growth prospects, financial health, and market positioning of these two industry players.

The details

The analysis finds that Waters Corporation has higher revenue and earnings than ENDRA Life Sciences, and is trading at a lower price-to-earnings ratio, indicating it is currently the more affordable of the two stocks. However, ENDRA Life Sciences has a much lower beta, meaning its share price is significantly less volatile than the overall market. Analysts also believe ENDRA Life Sciences has more potential upside, with a consensus target price suggesting over 550% possible gains compared to only around 3.6% for Waters.

  • The analysis is based on data as of January 29, 2026.

The players

Waters Corporation

A global analytical instrument manufacturing company that provides products and services for the pharmaceutical, life sciences, and materials industries.

ENDRA Life Sciences Inc.

A medical technology company developing innovative technologies to improve the capabilities of clinical diagnostic ultrasound, including for the treatment of nonalcoholic fatty liver disease.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights the differing strengths and growth prospects of these two medical technology companies. While Waters has the financial edge currently, ENDRA Life Sciences may offer more upside potential according to analyst projections. Investors will need to weigh these factors carefully to determine which stock best fits their investment objectives and risk tolerance.